CISA released a cybersecurity advisory detailing findings and activities from a Risk and Vulnerability Assessment conducted at a healthcare and public health organization in early 2023.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
